Sichenzia Ross Ference LLP Represents Immuron Limited in $20 Million Registered Direct Offering

Press Release – New York, NY – July 23, 2020 – Sichenzia Ross Ference LLP today announced that it represented Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, in a registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each ADS representing 40 of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately $20 million.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The offering was made pursuant to a shelf registration statement on Form F-3 (File No. 333-230762) previously declared effective by the U.S. Securities and Exchange Commission on April 17, 2019.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, and Avital Perlman, counsel Jeffrey Cahlon, and associate Matthew Siracusa.

• Author
• Recent Posts

Sichenzia Ross Ference Carmel LLP

SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

• Sichenzia Ross Ference Carmel LLP Represents Lexaria Bioscience Corp. in $2 Million Registered Direct Offering - April 28, 2025
• Sichenzia Ross Ference Carmel LLP Represents BriaCell Therapeutics in $13.8 Million Public Offering - April 28, 2025
• 美国思成律师事务所代表承销商D. Boral Capital完成凤凰亚洲纳斯达克上市 - April 28, 2025